With<unk>  being difficult to fully treat, the five-year survival rate is about 38-72% which typically decrease to 35-60% if there's no bone marrow transplantation performed. Generally older patients over 60 have a poor outlook due to prior health status before the diagnosis and the aggressive chemotherapy regimen used. The aggressive chemotherapy regimen can lead to long-term side effects such as prolonged anemia, leukocytopenia, neutropenia, and thrombocytopenia. The use of anthracycline drugs can cause a decrease in cardiac contractility, both short and long term. Those with AML-M4 inv(16) have a favorable prognosis with a five year overall survival rate of 61%.
Acute myelomonocytic leukemia
Prolymphocytic leukemia
Acute myeloblastic leukemia with maturation
Myeloid leukemia
Acute monocytic leukemia
Mixed-phenotype acute leukemia
Acute megakaryoblastic leukemia
Chronic myelomonocytic leukemia